Zai Lab Limited (ZLAB)

16,25 -0,34 (-2,05%) Börsenschluss: 04:00PM EDT

Zai Lab Limited

Jinchuang Plaza
Building 1, Fourth Floor 4560 Jinke Road Pudong
Shanghai 201210
China
86 21 6163 2588
https://www.zailaboratory.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 2.175

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Ying Du Ph.D.	Founder, Chairperson & CEO	1,7M	11,98M	1966
Mr. Joshua L. Smiley	President & COO	1,22M	N/A	1970
Dr. Rafael G. Amado M.D.	President and Head of Global Oncology Research & Development	1,6M	N/A	1964
Dr. Yajing Chen Ph.D.	Chief Financial Officer	624,56k	N/A	1968
Dr. Harald Reinhart M.D.	President and Head of Global Development for Neuroscience, Autoimmune & Infectious Diseases	951,03k	424,76k	1952
Dr. Peter Huang Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Ms. Christine Chiou	Senior VP & Head of Investor Relations	N/A	N/A	N/A
Mr. Frazor Titus Edmondson III, J.D.	Chief Legal Officer & Joint Corporate Secretary	829k	N/A	1966
Ms. Ann E. Beasley J.D.	Chief Compliance Officer	N/A	N/A	N/A
Dr. Ning Xu M.D.	Executive VP & Head of Clinical Operations	N/A	N/A	1965

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

Corporate Governance

Zai Lab Limiteds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.